Navigation Links
Arena Pharmaceuticals Announces Public Offering of Common Stock
Date:7/7/2009

SAN DIEGO, July 7, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for the offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on November 25, 2008, which became effective on December 3, 2008. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by telephone at 800.747.3924.

    Contact:  Jack Lief
              President and CEO

              Robert E. Hoffman
              VP, Finance and CFO
              Arena Pharmaceuticals, Inc.
              858.453.7200, ext. 222

www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
3. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
4. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
5. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
6. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
8. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
11. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Dr. Elyson ... wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental procedure, ... always problematic, they often are improperly erupted, resulting in risks of complications. By providing ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... of foundational nutrients that supports cellular and metabolic health. This synergistic combination of ... mg free-form curcumin, along with 150 mg of reduced glutathione and 200 mg ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of ... life forever with a same-day LASIK procedure at Christenbury Eye Center. The ... Jonathan Christenbury performed her surgery the same day as her in-office consultation and eye ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... industry, today announced that it was chosen as the Pharmaceutical News Provider of ... . The awards acknowledge the hard work and dedication of community members who ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco ... compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . ... retail starting at $59.95) uses 2 included CR-123 batteries to produce up to ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 3, 2016  As a teenager, an active ... fever, which damaged his heart. He continued enjoying sports ... June 2013, Shepherd,s heart was giving out and he ... June 20, 2013, the Mesa, Arizona ... (TAH-t). Like a heart transplant, the SynCardia TAH-t is ...
(Date:5/3/2016)... 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis ... of two patients who tell their personal story and encourage those at risk to get ... Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... is excited to announce the launch of its Mediceutical line of products, a line ... variety of clinical conditions. Founded in 2013, Forté spent more than two years researching ... http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
Breaking Medicine Technology: